DNB Asset Management AS Has $3.13 Million Stock Position in PROCEPT BioRobotics Corporation $PRCT
DNB Asset Management AS significantly increased its stake in PROCEPT BioRobotics Corporation by 213.9% in Q4, holding 99,567 shares valued at $3.13 million. Wall Street analysts maintain a "Hold" consensus rating with an average target price of $41.45, despite the company reporting strong Q1 revenue growth of 20.1% to $83.13 million, exceeding estimates. Insider activity shows mixed signals, with an executive selling shares while a director made a substantial purchase.
AllianceBernstein (PRCT) discloses 147,327 shares; 0.3% stake reported
AllianceBernstein L.P. has amended its Schedule 13G to report beneficial ownership of 147,327 shares of PROCEPT BioRobotics Corp Common Stock, representing a 0.3% stake. These shares are held in discretionary client accounts, with AllianceBernstein having sole voting power over 146,027 shares and sole dispositive power over all 147,327 shares. The filing, signed on May 15, 2026, indicates a passive investment and clarifies AllianceBernstein's independent management from its majority owner, Equitable Holdings, Inc.
A Look At PROCEPT BioRobotics (PRCT) Valuation As AUA Guideline Update Expands Aquablation Opportunity
PROCEPT BioRobotics (PRCT) is gaining attention after updated AUA guidelines supported its Aquablation therapy for BPH, including larger prostates. Despite a recent 2.83% share price increase, the stock is down 55.02% over the past year, trading 16.6% below the average analyst target. The most common valuation narrative suggests an undervalued price of $30.44 per share, contingent on continued procedure adoption and margin expansion.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Recommendation of "Hold" from Brokerages
PROCEPT BioRobotics (NASDAQ:PRCT) has received a consensus "Hold" rating from 14 research firms, with an average 1-year price target of $41.45. The company recently reported Q1 revenue of $83.13 million, exceeding estimates, though EPS was slightly worse than expected at -$0.56. Insider activity showed mixed signals, with a director purchasing shares and an EVP selling some, while institutional ownership remains high.
A Look At PROCEPT BioRobotics (PRCT) Valuation As AUA Guideline Update Expands Aquablation Opportunity
PROCEPT BioRobotics (PRCT) is back in the spotlight after updated AUA guidelines supported its Aquablation therapy for benign prostatic hyperplasia. Despite a 55.02% stock decline over the past year, the company is considered 14.2% undervalued with a fair value of $30.44 per share, driven by anticipated procedure adoption and margin expansion. Investors should consider potential risks like slower surgeon adoption or regulatory setbacks.
Pinnacle Associates Ltd. Takes Position in PROCEPT BioRobotics Corporation $PRCT
Pinnacle Associates Ltd. has initiated a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT), acquiring 123,194 shares valued at $3.88 million. This move comes amid mixed analyst sentiment, with some firms cutting price targets and Bank of America downgrading the stock to "underperform," contributing to a consensus "Hold" rating and an average target price of $41.45. PROCEPT BioRobotics reported Q4 revenue of $83.13 million, a 20.1% increase year over year, but missed EPS estimates with a loss of ($0.56).
Waterjet prostate surgery gets stronger support in new urology guidelines
PROCEPT BioRobotics (Nasdaq: PRCT) announced that updated American Urological Association (AUA) guidelines now strengthen the recommendation for Aquablation therapy as a surgical option for men with BPH and prostate volumes of 30–80 mL, and may be offered for larger prostates of 80–150 mL. This update is based on maturing clinical evidence, including randomized trials showing durable urinary symptom and flow improvements over five years. The company also noted that European Association of Urology (EAU) guidelines earlier this year issued a strong recommendation for Aquablation, signaling growing global support for the therapy.
Should PROCEPT BioRobotics’ Reaffirmed 2026 Outlook Amid Wider Losses Require Action From PRCT Investors?
PROCEPT BioRobotics (PRCT) reported wider net losses in Q1 2026 despite increased sales, reaffirming its full-year 2026 revenue outlook of US$390 million to US$410 million and a net loss up to US$91.50 million. The company's investment narrative hinges on Aquablation becoming a mainstream treatment, but ongoing losses highlight execution risks for investors. Analysis suggests a fair value of US$30.44, indicating a potential 20% upside from its current price, though some analysts predict prolonged losses.
Q1 Results Say a Lot About Procept Biorobotics Corp (PRCT) Stock Outlook
Procept Biorobotics Corp (NASDAQ: PRCT) reported strong Q1 2026 results, exceeding revenue forecasts with $83.1 million, a 20% year-over-year increase driven by increased sales of its Hydros robotic surgery system. Despite a wider loss per share of $0.56 due to higher expenses, the company maintains a strong cash position of $249 million. Management anticipates continued growth, projecting full-year 2026 revenue between $390 million and $410 million, reflecting 27% to 33% growth.
Mitsubishi UFJ Asset Management Co. Ltd. Has $5.38 Million Position in PROCEPT BioRobotics Corporation $PRCT
Mitsubishi UFJ Asset Management Co. Ltd. significantly increased its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 69.8% in the fourth quarter, now holding 174,739 shares valued at $5.38 million. Other institutional investors also raised their positions, with hedge funds and institutions owning 89.46% of the company's stock. Despite recent insider selling and a missed EPS estimate, the company reported 20.1% revenue growth year over year, though analysts maintain a cautious "Hold" rating with a consensus price target of $41.45.
C WorldWide Group Holding A S Purchases 225,000 Shares of PROCEPT BioRobotics Corporation $PRCT
C WorldWide Group Holding A S significantly increased its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 150% in the fourth quarter, purchasing an additional 225,000 shares. This brings their total holding to 375,000 shares, valued at approximately $11.8 million. The medical device company, specializing in robotic systems for BPH treatment with its AquaBeam Robotic System, reported mixed quarterly results including a 20.1% revenue increase year-over-year but missed EPS estimates.
A Look At PROCEPT BioRobotics (PRCT) Valuation After Q1 Earnings And Reaffirmed Growth Guidance
PROCEPT BioRobotics (PRCT) is under scrutiny after its Q1 earnings, which reported US$83.13 million in sales and a wider net loss, alongside reaffirmed 2026 revenue and loss guidance. The stock, currently trading at US$25.44, has seen recent rallies but still poses a question of limited upside versus potential for future growth. While a narrative suggests a 16.4% undervaluation, a market pricing perspective points to valuation risk given its P/S ratio of 4.5x compared to the industry average of 2.8x.
PRCT SEC Filings - Procept Biorobotics Corp 10-K, 10-Q, 8-K Forms
This page provides access to PROCEPT BioRobotics Corporation's (PRCT) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries for quick insights. Recent filings detail institutional ownership changes by T. Rowe Price and BNP Paribas, an 8.3% stake by FMR LLC, Q3 2025 revenue growth, and executive compensation updates and insider transactions. The platform aims to keep investors informed on PRCT's regulatory and financial disclosures.
Does Stronger Aquablation Tailwinds And Reaffirmed 2026 Guidance Change The Bull Case For PROCEPT (PRCT)?
PROCEPT BioRobotics (PRCT) reported increased Q1 2026 revenue but a wider net loss, with revenue up to US$83.13 million. The company reaffirmed its 2026 revenue guidance, citing strong European guideline support for its Aquablation therapy and AI software clearance. Despite these positive developments, the investment narrative focuses on the need for continued rapid adoption of Aquablation to justify ongoing losses and investment, with analysts providing varied fair value estimates for the stock.
Assessing PROCEPT BioRobotics (PRCT) Valuation After Mixed Q1 2026 Results And Share Price Weakness
PROCEPT BioRobotics (PRCT) is under scrutiny after reporting mixed Q1 2026 results, showing sales of US$83.13 million but a net loss of US$31.64 million. Despite a significant year-to-date share price decline, an analyst narrative suggests a 19.1% undervaluation, with a fair value of $30.44 per share, driven by anticipated growth in Aquablation technology and expanding market reach. However, continued operating losses and reliance on a single technology present risks to this growth story.
Latest PRCT News - PROCEPT BioRobotics Corporation Announces C...
This page provides the latest news and insights for PROCEPT BioRobotics Corporation (PRCT), a surgical robotics company specializing in urology. Key updates include details on their AquaBeam and HYDROS Robotic Systems, Aquablation therapy for BPH and prostate cancer, and financial performance. Recent announcements highlight the successful closing and pricing of its upsized initial public offering in September 2021.
PRCT SEC Filings - Procept Biorobotics Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of PROCEPT BioRobotics Corporation (PRCT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events. It details recent insider transactions, such as sales for tax withholding, stock grants, and share purchases by director-linked entities, ensuring investors have access to current regulatory disclosures. The platform also offers AI-powered summaries to quickly highlight key information from complex filings.
PROCEPT BioRobotics (PRCT) CTO reports share and option stakes
PROCEPT BioRobotics EVP and Chief Technology Officer Barry L. Templin has filed an initial ownership report (Form 3) detailing his equity stake and stock options in the company. The report shows that Templin directly holds 69,311 shares of Common Stock and indirectly holds 56,457 shares through the Templin Trust. Additionally, it lists various stock options with different exercise prices and expiration dates, which are subject to time-vesting schedules tied to his continued service.
PROCEPT BioRobotics (PRCT)’s Growth Narrative Improves Following Aquablation Upgrade and HYDROS Launch
PROCEPT BioRobotics (PRCT) has seen its growth narrative improve in mid-2026 due to two key developments. The European Association of Urology upgraded Aquablation therapy to a strong recommendation for benign prostatic hyperplasia, citing its effectiveness and preservation of ejaculatory function. Additionally, PROCEPT BioRobotics launched its HYDROS Robotic System internationally, designed to make Aquablation therapy more accessible and reproducible across various clinical settings.
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management will present at three investor conferences in May and June 2026. These conferences include the Bank of America Health Care Conference, the William Blair Growth Stock Conference, and the Truist Med-Tech Conference. The company, a surgical robotics firm focused on urology, will make presentations and hold fireside chats at these events.
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics announced that its management will present at three upcoming investor conferences in May and June 2026: the Bank of America Health Care Conference, the William Blair Growth Stock Conference, and the Truist Med-Tech Conference. The company, focused on advancing urology care with its AQUABEAM® and HYDROS® Robotic Systems, will have live webcasts and archived recordings of these events available on its investor relations website.
PROCEPT BioRobotics Q1 Loss Deepens To US$0.56 EPS And Tests Bullish Revenue Narratives
PROCEPT BioRobotics (PRCT) reported a Q1 2026 loss of US$0.56 EPS, deepening from previous quarters, despite revenue reaching US$83.1 million. While bullish narratives focus on strong revenue growth and future operating leverage from expanding Aquablation and HYDROS systems, bearish views highlight increasing losses ($102.5 million TTM) and no forecasted profitability in the next three years, questioning the current P/S valuation. The article advises investors to weigh these conflicting narratives and consider the full data before making investment decisions.
PROCEPT BioRobotics (NASDAQ: PRCT) Q1 2026 revenue rises 20%
PROCEPT BioRobotics reported a 20% increase in Q1 2026 revenue to $83.1 million, driven by higher system sales, consumables, and services, especially in the United States. Despite an improved gross margin of 65%, the company's net loss widened to $31.6 million due to increased spending on research, sales, and administration to support growth initiatives. As of March 31, 2026, the company had $245.6 million in cash and cash equivalents and an installed base of 971 robotic systems globally.
PROCEPT BioRobotics schedules 3 investor conference appearances
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management will participate in three investor conferences in May and June 2026: the Bank of America Health Care Conference, the William Blair Growth Stock Conference, and the Truist Med-Tech Conference. Live webcasts and archived recordings of these events will be available on the company's investor relations website for at least 90 days. The company, focused on surgical robotics for urology, will have either a fireside chat or a presentation at each event to discuss its advancements.
10 Best Robotics Stocks to Buy Under $30
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is highlighted as one of the best robotics stocks to buy under $30, driven by recent clinical and commercial advancements for its Aquablation therapy. The therapy received a strong recommendation from the European Association of Urology, positioning it as a preferred surgical option for BPH symptoms, and the company also launched its HYDROS Robotic System internationally. These developments are expected to expand treatment credibility and make the therapy more accessible and scalable.
Earnings call transcript: Procept Biorobotics Q1 2026 beats EPS expectations
Procept Biorobotics (PRCT) exceeded Q1 2026 EPS and revenue forecasts, reporting $0.56 EPS against an anticipated -$0.56, and $83.13 million in revenue. Despite strong financial performance, which included a 20% year-over-year revenue increase and a 65% gross margin, the stock declined by 5.73%, reflecting investor concerns over future profitability due to projected negative EPS. The company is focusing on operational excellence, commercial discipline, and international expansion, with executives expressing confidence in long-term growth driven by strategic realignments and product innovations.
PROCEPT BioRobotics (Nasdaq: PRCT) grows Q1 2026 revenue 20% but stays loss-making
PROCEPT BioRobotics (Nasdaq: PRCT) reported a 20% year-over-year revenue increase to $83.1 million in Q1 2026, driven by strong U.S. system and handpiece sales and international growth. Despite this, the company remained loss-making with a net loss of $31.6 million and an Adjusted EBITDA loss of $18.1 million due to increased operating expenses. PROCEPT reaffirmed its 2026 financial guidance, anticipating revenue between $390 million and $410 million and ongoing Adjusted EBITDA losses, while also announcing FDA clearance for its second-generation FirstAssist AI software.
12,200 U.S. procedures put PROCEPT BioRobotics' systems to work in Q1
PROCEPT BioRobotics reported Q1 2026 revenue of $83.1 million, a 20% year-over-year increase, with approximately 12,200 U.S. procedures performed using its systems, up 30%. The company reaffirmed its full-year 2026 revenue guidance of $390–$410 million and expects U.S. procedure growth of 39–48%, despite reporting a net loss of $31.6 million and an adjusted EBITDA loss of $18.1 million for the quarter. Market reaction was positive, with PRCT stock gaining 11.84% following the news, and the company also announced FDA clearance for its second-generation FirstAssist AI™ software.
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics (PRCT) reported a Q1 loss of $0.56 per share, slightly wider than the Zacks Consensus Estimate of a $0.55 loss, but exceeded revenue expectations with $83.13 million against an estimate of $80.29 million. Despite this, the company's shares have fallen 26.8% year-to-date, underperforming the S&P 500. The stock currently holds a Zacks Rank #2 (Buy), indicating potential for market outperformance.
Procept Biorobotics in the spotlight as Q1 earnings test turnaround
Procept Biorobotics Corp. is reporting its first-quarter earnings, a critical event following a disappointing Q4 that saw its shares drop significantly. Investors are looking for execution proof and how management's strategy to deepen engagement with existing customers, rather than just new placements, will impact profitability. Analysts have mixed ratings, with expectations of a continued loss but stable revenue, highlighting the importance of the upcoming announcement.
PROCEPT BioRobotics (NASDAQ:PRCT) Rating Increased to Sell at Wall Street Zen
Wall Street Zen upgraded PROCEPT BioRobotics (NASDAQ:PRCT) from a "strong sell" to a "sell" rating. This upgrade comes despite mixed analyst coverage overall, with a consensus "Hold" rating and a target price of $40.82. The company recently missed its earnings expectations, reporting an EPS of ($0.53) against an expected ($0.32) and revenue of $76.38M versus $93.7M.
PROCEPT BioRobotics (NASDAQ: PRCT) executive discloses initial stock and option stakes
PROCEPT BioRobotics Chief Strategy and Marketing Officer Pooja Sharma has reported her initial insider holdings. She beneficially owns 87,559 shares of common stock, including restricted stock units that vest over time. Additionally, Sharma holds stock options for 29,615 shares at an exercise price of $25.35 and options for 85,929 shares at an exercise price of $31.92, both with vesting schedules contingent on continued employment.
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock
Chicago Capital, LLC significantly increased its stake in PROCEPT BioRobotics (NASDAQ:PRCT) by adding 969,592 shares, an estimated $27.32 million investment, during the first quarter of 2026. This move reflects the firm's strategy to acquire shares of PROCEPT BioRobotics, which has seen its stock price decline substantially, yet continues to demonstrate strong growth in procedures and improved EBITDA margins. The company, known for its AquaBeam Robotic System for urologic surgery, is viewed by some as an attractive high-risk, high-reward opportunity for healthcare-savvy investors due to its growth potential and discounted sales multiple.
Procept BioRobotics stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating on Procept BioRobotics (NASDAQ: PRCT) with a $34.00 price target, citing confidence in the company's growth opportunities despite a challenging fourth quarter and recent guidance cut. The firm expects an in-line first quarter, which could boost the stock ahead of its April 29th earnings report. This positive outlook comes amid recent company developments including the international launch of its HYDROS Robotic System and a new board appointment.
Procept BioRobotics stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating on Procept BioRobotics Corp (NASDAQ:PRCT) with a $34.00 price target, citing confidence in the company's growth opportunities despite a challenging fourth quarter. The firm expects an in-line first quarter, which it believes will boost the stock, and anticipates more clarity when the company reports earnings on April 29. This follows recent developments including the international launch of its HYDROS Robotic System in the UK and new board appointments.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Recommendation of "Hold" from Brokerages
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received a consensus "Hold" rating from fourteen brokerages, with an average 1-year price objective of $40.82. The company recently missed earnings expectations, reporting ($0.53) EPS against an anticipated ($0.32) and revenue of $76.38 million versus $93.7 million expected. Despite the earnings miss, significant insider buying activity was noted, with Director Antal Rohit Desai purchasing nearly 100,000 shares.
Precision Trading with Procept Biorobotics Corporation (PRCT) Risk Zones
This article analyzes Procept Biorobotics Corporation (PRCT), highlighting stable neutral readings in shorter horizons that could signal an easing of a long-term weak bias. It outlines an exceptional 79.4:1 risk-reward short setup and provides three distinct AI-generated trading strategies tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis and current support/resistance levels.
PRCT | PROCEPT BioRobotics Corporation Common Executive Compensation
This page from Quiver Quantitative provides an overview of PROCEPT BioRobotics Corporation (PRCT), focusing on executive compensation and various other financial data points. It includes sections on insider trading, institutional holdings, corporate lobbying, US patents, government contracts, news, analyst ratings, and smart scores, but displays "No data" for several of these categories for PRCT. The company is described as a surgical robotics firm specializing in urology, known for its AquaBeam and HYDROS Robotic Systems.
How many employees work at PROCEPT BioRobotics?
PROCEPT BioRobotics Corp. currently has 984 employees, showing a year-over-year growth rate of 23.2%. The company specializes in surgical robotics, particularly the AQUABEAM Robotic System for treating benign prostatic hyperplasia (BPH). Employee headcount has consistently grown since 2022, and key workforce metrics like average salary, tenure, and job postings are also tracked.
PROCEPT BioRobotics Corp ($PRCT) CEO 2025 Pay Revealed
PROCEPT BioRobotics Corp's CEO, Larry L. Wood, is estimated to have received $15,074,745 in compensation in 2025, based on a recent SEC filing. The article also details recent insider trading activity, institutional holdings changes, and analyst ratings with price targets for PRCT stock. Key institutional investors like FMR LLC and BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. have significantly adjusted their positions.
PROCEPT BioRobotics (NASDAQ: PRCT) details 2026 virtual meeting and pay vote
PROCEPT BioRobotics (NASDAQ: PRCT) announced its fully virtual 2026 annual shareholder meeting for June 9, 2026, where stockholders will vote on director elections, auditor ratification, and executive compensation on an advisory basis. The company reported strong 2025 financial results with revenue of $308.1 million and 43,300 U.S. procedures, alongside a leadership transition appointing Larry L. Wood as CEO. The proxy statement details executive compensation, including specific one-time agreements for the outgoing and incoming CEOs, and reaffirms the company's pay-for-performance philosophy with significant portions of executive compensation tied to financial and stock performance.
Assessing PROCEPT BioRobotics (PRCT) Valuation After Strong Q3 2025 Update And 2026 Outlook
PROCEPT BioRobotics (PRCT) reported strong Q3 2025 results and issued a 2026 revenue outlook of US$410 million to US$430 million, despite recent share price declines. While a narrative fair value suggests the stock is 19.5% undervalued at $30.44, another view highlights its current P/S ratio of 4.5x sales, which is higher than the estimated fair ratio of 3x and the industry average of 2.8x, indicating investors may be paying a premium. The company's future hinges on the successful adoption and utilization of its HYDROS robotic system and Aquablation technology in a competitive BPH market.
PROCEPT BioRobotics (PRCT) price target decreased by 37.60% to 33.58
PROCEPT BioRobotics (PRCT) has seen its price target reduced by 37.60% to $33.58. This adjustment may reflect updated analyst expectations or recent company performance. Investors should monitor PRCT for further developments.
PROCEPT BioRobotics (PRCT) Is Up 7.5% After Raising 2026 Revenue Outlook And Sharpening Growth Focus
PROCEPT BioRobotics (PRCT) saw its stock rise 7.5% after reporting strong Q3 2025 results and issuing a 2026 revenue outlook of US$410 million to US$430 million. The company is focusing on improving procedure utilization within its existing customer base and has received a strong recommendation for Aquablation from the European Association of Urology. Despite the appealing growth story, potential risks include reimbursement pressure and a shift towards outpatient settings.
PROCEPT BioRobotics (PRCT) Projected to Post Earnings on Thursday
PROCEPT BioRobotics (PRCT) is expected to release its Q1 2026 earnings on Thursday, April 23rd, with analysts forecasting a loss of ($0.5528) EPS and revenue of $80.65M. The company missed previous estimates, and analysts project negative EPS for the current and next fiscal years. Insider buying and institutional ownership have been notable, despite a "Hold" average rating from analysts.
PROCEPT BioRobotics (PRCT) Is Up 7.5% After Raising 2026 Revenue Outlook And Sharpening Growth Focus
PROCEPT BioRobotics (PRCT) shares rose 7.5% after the company reported strong Q3 2025 results and increased its fiscal 2026 revenue outlook to between US$410 million and US$430 million. The company is shifting its focus from new system placements to improving procedure utilization within its existing customer base. This updated strategy, supported by a strong recommendation for Aquablation from the European Association of Urology, aims to drive deeper engagement and long-term value.
Wells Fargo lowers Procept BioRobotics target after weak Q4 performance
Wells Fargo has reduced its price target for Procept BioRobotics following a weaker-than-expected fourth-quarter performance. The adjustment reflects concerns over the company's recent financial results and outlook.
Wells Fargo lowers Procept BioRobotics target after weak Q4 performance
Wells Fargo has reduced its price target for Procept BioRobotics following the company's weaker-than-anticipated fourth-quarter financial performance. The firm maintains an "Equal Weight" rating on the stock, citing concerns about growth.
Baillie Gifford & Co. Purchases 157,147 Shares of PROCEPT BioRobotics Corporation $PRCT
Baillie Gifford & Co. increased its stake in PROCEPT BioRobotics Corporation by 18.3% in Q4, acquiring 157,147 additional shares, bringing their total to 1,015,978 shares valued at $31.96 million. Despite this institutional buying, PROCEPT BioRobotics missed quarterly earnings and revenue expectations, leading to several price target reductions and a "Hold" consensus rating from analysts. Insider activity shows significant acquisition by a director, although the company's financial performance highlights challenges in meeting market estimates.
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced that it will report its first quarter 2026 financial results after market close on Wednesday, April 29, 2026. The company will host a conference call at 4:30 p.m. Eastern Time for investors to discuss the results. Live audio and an archived recording of the webcast will be available on the "Investors" section of the company's website.
